BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced its first collaborations with health systems in pursuit of their shared goal to improve and simplify Alzheimer’s disease (AD) diagnosis.

马萨诸塞州比勒里卡（商业新闻短讯）--Quanterix Corporation（纳斯达克：QTRX）是超灵敏研究产品和高清诊断的领先供应商，今天宣布与卫生系统进行首次合作，以实现改善和简化阿尔茨海默氏病（AD）诊断的共同目标。

These relationships further the company’s goal to build the global infrastructure necessary for AD testing by expanding clinical access to Quanterix’s leading blood biomarker assays..

这些关系进一步推动了该公司的目标，即通过扩大临床对Quanterix领先的血液生物标志物检测的访问，建立AD检测所需的全球基础设施。。

Collectively AdventHealth, Mass General Brigham, Mayo Clinic, South Carolina Alzheimer's Disease Research Center (SC-ADRC) at the Medical University of South Carolina, and UPMC represent 140+ hospitals across 18 states, caring for approximately 21 million patients in their hospital networks. This reach will provide greater access to patients for high-accuracy, non-invasive AD testing.

AdventHealth、Mass General Brigham、Mayo Clinic、南卡罗来纳医科大学南卡罗来纳州阿尔茨海默氏病研究中心（SC-ADRC）和UPMC代表了18个州的140多家医院，在他们的医院网络中照顾了大约2100万患者。这一范围将为患者提供更大的机会进行高精度，无创的AD检测。

Quanterix can enable health systems to access Alzheimer’s blood biomarker tests through a variety of models, including sample processing through Lucent Diagnostics, Quanterix’s diagnostic testing brand, or by installing Simoa technology in-house to develop and validate their own Laboratory Developed Tests (LDTs)..

Quanterix可以使卫生系统通过各种模型访问阿尔茨海默氏病血液生物标志物测试，包括通过朗讯诊断（Lucent Diagnostics）、Quanterix诊断测试品牌进行样本处理，或者通过在内部安装Simoa技术来开发和验证自己的实验室开发测试（LDT）。。

Blood-based biomarker testing offers Alzheimer’s patients a non-invasive method and greater access to AD testing overall. Traditional AD diagnosis has relied on combination of symptom presentation, brain imaging, and the detection of CSF biomarkers for AD. This approach is not only burdensome and invasive for patients, but also costly, making them unsuitable for most primary and secondary care settings1.

基于血液的生物标志物检测为阿尔茨海默氏病患者提供了一种非侵入性方法，并为AD检测提供了更多的途径。传统的AD诊断依赖于症状表现，脑成像和AD脑脊液生物标志物检测的结合。这种方法不仅对患者来说是繁重和侵入性的，而且成本高昂，使其不适合大多数初级和二级保健设置1。

This inaccessibility has left 50-70% of symptomatic AD patients without a correct and timely diagnosis, impacting quality of life, medical autonomy, and general wellbeing1. With 15 million Americans predicted to be affected by Alzheimer’s by 2060,2 high-accuracy, easily accessible blood testing will play a critical role in early detection and treatment of Alzheimer’s.

这种不可接近性使50-70%的有症状AD患者没有正确及时的诊断，影响了生活质量，医疗自主性和总体健康1。预计到2060年将有1500万美国人受到阿尔茨海默氏病的影响，2高精度，易于获取的血液检测将在阿尔茨海默氏病的早期发现和治疗中发挥关键作用。

Quanterix’s Simoa p-Tau 217 assays provide high accuracy, consistent with the recommendations in the recent NIA-AA criteria for Alzheimer’s diagnosis3, stating that p-Tau 217 is the only plasma biomarker appropriate for Alzheimer’s diagnosis..

Quanterix的Simoa p-Tau 217检测方法具有很高的准确性，与最近NIA-AA阿尔茨海默氏病诊断标准3中的建议一致，指出p-Tau 217是唯一适合阿尔茨海默氏病诊断的血浆生物标志物。。

“New resources available to aid in diagnosis and treatment of Alzheimer's disease have contributed to a more optimistic environment for AD patient care,” said Kirk Erickson, PhD, director of translational neuroscience at the AdventHealth Neuroscience Institute. “With simplified, affordable, non-invasive testing methods, physicians can proactively evaluate and monitor patients with memory concerns.

AdventHealth神经科学研究所（AdventHealth neuroscience Institute）转化神经科学主任柯克·埃里克森（KirkErickson）博士说：“可用于帮助诊断和治疗阿尔茨海默氏病的新资源为AD患者护理提供了更乐观的环境。”。“通过简化、负担得起、无创的测试方法，医生可以主动评估和监测有记忆问题的患者。

The availability of blood-based biomarker testing to the AdventHealth network has the potential to help a wide population concerned about mild cognitive impairment and aid physicians in their diagnosis.”.

AdventHealth网络提供基于血液的生物标志物测试有可能帮助广泛关注轻度认知障碍的人群，并帮助医生进行诊断。”。

'As we see how well blood measures of p-Tau 217 perform,' said Dr. Brad Dickerson, MD of Mass General Neurology and Harvard Medical School, 'it is exciting to plan for this new tool in our workflow to make an early, accurate diagnosis if a patient is suspected of having Alzheimer's disease.'

哈佛医学院大众普通神经病学医学博士布拉德·迪克森（BradDickerson）博士说：“当我们看到血液中p-Tau 217的检测效果如何时，在我们的工作流程中计划使用这种新工具，以便在怀疑患者患有阿尔茨海默氏病的情况下做出早期准确的诊断，这令人兴奋。”

“In our pursuit to build the global testing infrastructure for Alzheimer’s disease, Quanterix is pleased to work with several health systems whose combined networks treat millions of patients,” said Masoud Toloue, CEO of Quanterix. “There is a critical need for easily accessible, time- and cost-effective diagnostic tools for Alzheimer’s.

Quanterix首席执行官Masoud Toloue说：“在我们致力于建立全球阿尔茨海默病检测基础设施的过程中，Quanterix很高兴与多个医疗系统合作，这些医疗系统的联合网络可以治疗数百万患者。现在迫切需要一种易于获取、具有时间和成本效益的阿尔茨海默病诊断工具。

By working with these leading hospitals, we are taking an important step just as disease modifying therapies become available to patients suffering from this disease..

通过与这些领先的医院合作，我们正在迈出重要的一步，就像患有这种疾病的患者可以使用疾病缓解疗法一样。。

Quanterix’s commitment to establishing the industry standard for accuracy continues to position the company as a critical partner for AD testing. Beyond these five health systems, Quanterix is initiating partnerships with reference laboratories and hospitals globally to enable patients with cognitive symptoms consistent with Alzheimer’s disease to be tested..

Quanterix致力于建立准确度的行业标准，继续将公司定位为广告测试的关键合作伙伴。除了这五个卫生系统之外，Quanterix正在与全球参考实验室和医院建立合作伙伴关系，以便对患有阿尔茨海默氏病认知症状的患者进行检测。。

For more information about Quanterix’s work in neurology, visit: https://www.quanterix.com/therapeutic-areas/neurology/.

有关Quanterix在神经病学方面工作的更多信息，请访问：https://www.quanterix.com/therapeutic-areas/neurology/.

About Quanterix

关于Quanterix

From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Limit of Quantification (LoQ) of conventional analog methods.

从发现到诊断，Quanterix的超灵敏生物标志物检测正在推动突破，只有通过其无与伦比的灵敏度和灵活性才能实现。该公司的Simoa®技术为血液，血清或血浆中的早期生物标志物检测提供了金标准，能够量化远低于常规类似方法定量限（LoQ）的蛋白质。

Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,700 peer-reviewed journals.

其业界领先的精密仪器、数字免疫分析技术和CLIA认证的加速器实验室支持了促进神经病学、肿瘤学、免疫学、心脏病学和传染病疾病理解和管理的研究。近二十年来，Quanterix一直是科学界值得信赖的合作伙伴，为2700多种同行评审期刊上发表的研究提供了动力。

Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn..

有关这家位于马萨诸塞州Billerica的公司的更多信息，请访问https://www.quanterix.com或者在Twitter和LinkedIn上关注我们。。

About Lucent Diagnostics

关于朗讯诊断

Committed to transforming the landscape of Alzheimer’s Disease (AD) diagnostic testing, Lucent Diagnostics, a Quanterix brand, is revolutionizing AD patient care by providing accurate, reliable, and actionable diagnostic information to healthcare professionals and patients alike. Lucent Diagnostics harnesses Quanterix’s ultrasensitive Simoa® technology—the groundbreaking biomarker detection technology that delivers the gold standard for earlier biomarker detection in blood, serum or plasma— to power its mission of addressing the critical need for advanced diagnostic tools that can measure biomarkers associated with neurodegenerative diseases.

Quanterix品牌朗讯诊断公司致力于改变阿尔茨海默病（AD）诊断测试的格局，通过向医疗保健专业人员和患者提供准确，可靠和可行的诊断信息，正在彻底改变AD患者护理。朗讯诊断利用Quanterix的超灵敏Simoa®技术，这是一种开创性的生物标志物检测技术，为血液，血清或血浆中的早期生物标志物检测提供了金标准，从而为其解决对先进诊断工具的迫切需求提供了动力，这些工具可以测量与神经退行性疾病相关的生物标志物。

The LucentAD test, powered by Simoa®, is available to healthcare providers as an aid in conjunction with other diagnostic tools, provides clinicians with a simplified process to quickly assess the likelihood of a patient having amyloid pathology consistent with AD, allowing for early or preventative AD treatment.

由Simoa®提供支持的LucentAD测试可与其他诊断工具一起提供给医疗保健提供者，为临床医生提供了一个简化的过程，以快速评估患者患有与AD一致的淀粉样蛋白病理的可能性，从而允许早期或预防性AD治疗。

The LucentAD product line currently measures p-Tau 181 and p-Tau 217 in plasma, two of the top performing biomarkers for AD. Find additional information about the Billerica, Massachusetts-based company at https://www.lucentdiagnostics.com/ or follow us on Twitter and LinkedIn..

LucentAD产品线目前测量血浆中的p-Tau 181和p-Tau 217，这是AD表现最好的两种生物标志物。有关这家位于马萨诸塞州Billerica的公司的更多信息，请访问https://www.lucentdiagnostics.com/或者在Twitter和LinkedIn上关注我们。。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements.

本新闻稿包含1995年《私人证券诉讼改革法案》所指的前瞻性声明。诸如“可能”、“将”、“预期”、“计划”、“预期”、“估计”、“打算”等词语和类似表达（以及其他涉及未来事件、条件或情况的词语或表达）旨在识别前瞻性陈述。

Forward-looking statements in this news release are based on Quanterix’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’s filings with the U.S.

本新闻稿中的前瞻性陈述基于Quanterix截至本新闻稿发布之日的预期和假设。这些前瞻性陈述都涉及风险和不确定性。Quanterix向美国提交的文件中讨论了可能导致Quanterix的实际结果与本新闻稿中前瞻性声明中明示或暗示的结果不同的因素。

Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available..

证券交易委员会，包括其中包含的“风险因素”部分。除法律要求外，Quanterix不承担更新本文所含任何前瞻性声明以反映预期变化的义务，即使有新信息可用。。

________________________

________________________

1 Hansson O, Edelmayer RM, Boxer AL, et al. The Alzheimer’s Association appropriate use recommendations for blood biomarkers in Alzheimer’s disease. Alzheimers Dement. 2022;18(12):2669-2686. doi:10.1002/alz.12756

1 Hansson O，Edelmayer RM，Boxer等人。阿尔茨海默病协会对阿尔茨海默病血液生物标志物的适当使用建议。阿尔茨海默病。2022年；18（12）：2669-2686。doi:10.1002/alz.12756

2 Brookmeyer R, Abdalla N, Kawas CH, Corrada MM. Forecasting the prevalence of preclinical and clinical Alzheimer’s disease in the United States. Alzheimers Dement. 2018;14(2):121-129. doi:10.1016/j.jalz.2017.10.009

2 Brookmeyer R，Abdalla N，Kawas CH，Corrada MM。预测美国临床前和临床阿尔茨海默病的患病率。阿尔茨海默病。2018年；14（2）：121-129。doi:10.1016/j.jalz.2017.10.009

3 Draft NIA-AA Revised Criteria for Diagnosis and Staging of Alzheimer's Disease, published October 2023.

3 NIA-AA修订的阿尔茨海默病诊断和分期标准草案，2023年10月发布。